MYLIP Activators
MYLIP activators comprise a range of chemical compounds that indirectly enhance the functional activity of MYLIP by influencing various signaling pathways. Compounds such as Forskolin and Isoproterenol increase intracellular levels of cAMP, indirectly promoting MYLIP's functional role through PKA activation, which is crucial for the phosphorylation events that MYLIP might regulate. Similarly, IBMX sustains PKA activity by preventing cAMP breakdown, thereby facilitating MYLIP's involvement in ubiquitinating target proteins for degradation. Phorbol 12-myristate 13-acetate (PMA) acts as a PKC activator, potentially increasing MYLIP activity related to cholesterol regulation and receptor internalization, while 8-Bromo-cAMP, a cAMP analog, directly stimulates PKA, enhancing MYLIP's association with cellular membranes and lipid homeostasis.
Moreover, Lithium Chloride and Sodium Fluoride, through the inhibition of GSK-3 and protein phosphatases respectively, mayenhance MYLIP's activity by modulating phosphorylation states of proteins that interact with or regulate MYLIP. Rolipram's inhibition of PDE4 and Okadaic Acid's inhibition of protein phosphatases 1 and 2A both contribute to increased cAMP and phosphorylation levels, augmenting MYLIP's role in protein trafficking. The beta-adrenergic effects of Isoproterenol also elevate cAMP, further supporting PKA-mediated enhancement of MYLIP's functions. Anisomycin, through activation of SAPKs, and Staurosporine, despite its broad kinase inhibition, may selectively activate cellular stress pathways that implicate MYLIP. Lastly, Epigallocatechin Gallate (EGCG) inhibits protein kinases, possibly altering MYLIP's substrate specificity and degradation pathways, thereby promoting its activity within the cell. Collectively, these activators operate through distinct yet convergent mechanisms that culminate in the upregulation of MYLIP's role in lipid metabolism and protein ubiquitination without directly increasing its expression or intrinsic activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin increases intracellular cAMP levels, which enhances the activity of MYLIP by activating PKA. PKA phosphorylation can then lead to downstream effects that increase the functional activity of MYLIP in its role in lipid metabolism and endocytic processes. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP, thereby sustaining PKA activity. This prolonged PKA activity can indirectly enhance MYLIP function by maintaining its role in mediating the ubiquitination and degradation of target proteins. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate MYLIP or related regulatory proteins, leading to an increase in MYLIP activity involved in cholesterol regulation and receptor internalization. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that directly activates PKA. PKA activation can enhance MYLIP activity by promoting its association with cellular membranes where it exerts its effects on lipid homeostasis. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3). Since GSK-3 can phosphorylate proteins that regulate MYLIP, inhibition by lithium chloride may potentiate MYLIP's activity in protein ubiquitination and degradation. | ||||||
Sodium Fluoride | 7681-49-4 | sc-24988A sc-24988 sc-24988B | 5 g 100 g 500 g | $40.00 $46.00 $100.00 | 26 | |
Sodium fluoride acts as a nonspecific inhibitor of protein phosphatases, leading to increased phosphorylation levels of proteins within the cell. This could result in enhanced MYLIP activity through a sustained phosphorylated state of proteins in signaling pathways involving MYLIP. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels and subsequent activation of PKA. Activated PKA may then enhance MYLIP activity through phosphorylation events. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A, which leads to increased phosphorylation within the cell. This elevated phosphorylation state can indirectly enhance the activity of MYLIP in its role in protein trafficking. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels, which in turn activates PKA. PKA activation can enhance MYLIP activity by promoting lipid metabolism processes in which MYLIP is involved. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin activates stress-activated protein kinases (SAPKs), which can lead to the activation of MYLIP through stress-induced signaling pathways that MYLIP is implicated in. | ||||||